Research Analysts Offer Predictions for ELEV Q2 Earnings

Elevation Oncology, Inc. (NASDAQ:ELEV) – William Blair issued their Q2 2025 EPS estimates for Elevation Oncology in a research note issued to investors on Friday, March 7th. William Blair analyst A. Hsieh forecasts that the company will post earnings per share of ($0.21) for the quarter. William Blair currently has a “Outperform” rating and a $5.00 price objective on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. William Blair also issued estimates for Elevation Oncology’s Q3 2025 earnings at ($0.21) EPS and Q4 2025 earnings at ($0.24) EPS.

Elevation Oncology (NASDAQ:ELEV) last posted its earnings results on Thursday, March 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04.

A number of other brokerages have also recently commented on ELEV. JMP Securities restated a “market outperform” rating and set a $7.00 target price on shares of Elevation Oncology in a report on Thursday, December 19th. Stephens reissued an “overweight” rating and set a $5.00 price target on shares of Elevation Oncology in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Elevation Oncology in a report on Tuesday, January 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Elevation Oncology presently has a consensus rating of “Buy” and an average price target of $6.83.

Elevation Oncology Trading Down 0.0 %

ELEV opened at $0.51 on Monday. Elevation Oncology has a 52 week low of $0.41 and a 52 week high of $5.83. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. The business has a fifty day simple moving average of $0.64 and a 200-day simple moving average of $0.62. The firm has a market cap of $30.20 million, a P/E ratio of -0.62 and a beta of 1.37.

Institutional Trading of Elevation Oncology

A number of large investors have recently made changes to their positions in ELEV. Velan Capital Investment Management LP purchased a new stake in shares of Elevation Oncology in the 4th quarter valued at approximately $25,000. Two Sigma Advisers LP raised its stake in Elevation Oncology by 47.8% in the fourth quarter. Two Sigma Advisers LP now owns 84,400 shares of the company’s stock valued at $47,000 after buying an additional 27,300 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in shares of Elevation Oncology in the 4th quarter valued at about $113,000. Millennium Management LLC raised its position in shares of Elevation Oncology by 3.9% during the 4th quarter. Millennium Management LLC now owns 815,916 shares of the company’s stock worth $459,000 after acquiring an additional 30,466 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in Elevation Oncology by 550.5% during the fourth quarter. Deutsche Bank AG now owns 188,771 shares of the company’s stock worth $106,000 after purchasing an additional 159,751 shares during the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.